A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs AT 406 (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms GORTEC
- Sponsors Debiopharm
- 30 Sep 2019 Results published in the Debiopharm Media Release.
- 30 Sep 2019 According to an Debiopharm media release, results from this study were presented today, at the ESMO Congress (European Society for Medical Oncology).
- 03 Sep 2019 Status changed from active, no longer recruiting to completed, according to a Debiopharm media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History